Most patients with advanced non-small cell lung cancer (NSCLC) do not respond to programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis blockade, highlighting the need for the identification of new targets for immune checkpoint inhibition. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.